ALPPS, or “in-situ split liver resection”—as it is still called in our center in Regensburg—has elicited a huge hype among surgeons worldwide over the last 10 years. In the year 2008, we did the first case of surgery with this new technique, more or less by accident, in a patient with perihilar carcinoma [1]. Intraoperatively, the tumor in this rather young patient appeared technically resectable, but the left lateral lobe—the prospected functional liver remnant—as definitively much too small for appropriate function. Therefore, I thought about an alternative: I came up with the idea to perform the parenchymal dissection along the falciform ligament, divide the left hepatic bile duct at the basis of the round ligament, and suture-close the central stump, which appeared tumor-free. Then I decided to divide the right portal vein (like for resection and as an intraop. Alternative to interventional embolization for hypertrophy induction) and finally performed a hepatico-jejunostomy to the dilated left-lateral bile duct. Drains were placed, and the abdomen was closed to wait for hypertrophy of the left-lateral liver lobe. Interestingly, when we performed a CT scan about 8 days after this procedure, we saw a massive hypertrophy of the left-lateral lobe and, therefore, decided to perform the second step of the operation, i.e., the completion of extended right hepatectomy already by day 10 after the first operation. The postoperative course was unproblematic, with appropriate liver function from the beginning. Misfortunately, the patient died about 1 year later due to peritoneal carcinomatosis: in the resection specimen microscopic evidence of peritoneal carcinomatosis at the lesser omentum had been found, explaining the bad oncologic outcome. In terms of technical and functional outcome, however, the operation had to be regarded as an absolute success. Subsequently, we performed this procedure on average in 2–3 patients per year (out of about 150–180 liver resections per year in our center), i.e., we saw an indication for ALLPS in only about 2% of our patients.